SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
179 hedge funds and large institutions have $198M invested in SANGAMO THERAPEUTICS INC in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 40 reducing their positions, and 23 closing their positions.
125% more call options, than puts
Call options by funds: $248K | Put options by funds: $110K
88% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 40
3.16% more ownership
Funds ownership: 63.44% → 66.6% (+3.2%)
4% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 23
2% less funds holding
Funds holding: 182 → 179 (-3)
37% less capital invested
Capital invested by funds: $315M → $198M (-$118M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
+$9.84M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.22M |
| 3 |
Renaissance Technologies
New York
|
+$3.18M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$3.11M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.56M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.36M |
| 3 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$1.91M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.44M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.1M |
SGMO Hedge Fund Activity: Q1 2023 in Review
179 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2023, worth a combined $198M — down 37% from $315M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SGMO and 22 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 75 added.
The largest buyer was Rokos Capital Management (UK), adding an estimated $9.84M. The largest seller was Nuveen, cutting an estimated $5.56M.
- 179 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2023, down from 182 in Q4 2022.
- Funds reported $198M of SANGAMO THERAPEUTICS INC stock for Q1 2023, down 37% quarter-over-quarter.
- 22 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2023 and 23 closed out, a net change of -1 holder.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2023 was Rokos Capital Management (UK), an estimated $9.84M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2023 was Nuveen, an estimated $5.56M sold.
Based on aggregated 13F filings for Q1 2023.